Chemomab Therapeutics (CMMB) to Release Quarterly Earnings on Wednesday

Chemomab Therapeutics (NASDAQ:CMMB) will likely be issuing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Chemomab Therapeutics to post earnings of ($0.04) per share for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 21, 2026 at 12:30 PM ET.

Chemomab Therapeutics (NASDAQ:CMMB) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). On average, analysts expect Chemomab Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Chemomab Therapeutics Trading Up 1.7%

Shares of CMMB opened at $1.77 on Friday. Chemomab Therapeutics has a 12 month low of $1.35 and a 12 month high of $5.88. The firm’s 50 day moving average is $1.71 and its 200-day moving average is $1.99. The stock has a market capitalization of $12.73 million, a PE ratio of -0.69 and a beta of 0.51.

Hedge Funds Weigh In On Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. XTX Topco Ltd bought a new stake in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 19,013 shares of the company’s stock, valued at approximately $31,000. XTX Topco Ltd owned 0.31% of Chemomab Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.